Phase I Study of VLX-1005 in Healthy Subjects

Safety and Tolerability in Healthy Volunteers Clinical Trial

Official title:
A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects

Status Completed

Clinical Trial Summary

The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration. Other exploratory objectives are: To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Safety and Tolerability in Healthy Volunteers

Clinical Trial Details

NCT number	NCT04783545
Study type	Interventional
Source	Veralox Therapeutics
Contact
Status	Completed
Phase	Phase 1
Start date	March 24, 2021
Completion date	January 11, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03672604` - A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects	Phase 1
Completed	`NCT04535752` - A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)	Phase 1
Completed	`NCT01955564` - A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.	Phase 1
Completed	`NCT04034784` - Discrete(TM) Safety Clinical Trial GLAD-01	N/A
Terminated	`NCT03010046` - Single Dose Study of ANX005 in Healthy Volunteers	Phase 1